The NIH Center for Interventional Oncology is an interdisciplinary effort with the primary goal of developing and better defining novel local, regional, or combination cancer therapies in patients with localized or organ-confined neoplasms. The mechanisms by which this goal will be achieved will include collaborations between imaging scientists, interventional radiologists, oncologists (surgical, medical, radiation, or urological), biologists and engineers. The CIO will provide a translational environment wherein clinical shortcomings in oncology are identified, then addressed by a collaborative team that develop novel technologies and techniques. Minimally invasive therapies are often less costly, safer, and easy to translate and broadly apply in the setting of the NIH Clinical Center and Intramural Research Program. The new Center for Interventional Oncology (CIO) was established in Q3-4 FY 09 at the NIH Clinical Center (CC) to develop and translate image-guided technologies for localized cancer treatments. The Center is a collaboration involving the CC, National Cancer Institute (NCI), the National Heart, Lung, and Blood Institute (NHLBI), and the National Institute of Bioimaging and Bioengineering (NIBIB). The Center will draw on the strengths of each institute to investigate how imaging technologies and advanced devices can diagnose and treat localized cancers in ways that are precisely targeted and minimally or non-invasive. It will also help bridge the gap between diagnosis and therapy, and between emerging technology and procedural medicine. Advanced imaging methods have ushered in an era of earlier detection of cancers that are frequently localized to a single organ or region. Interventional oncology often provides cancer patients with local or regional treatment options to augment the standard cancer treatment options: systemic chemotherapy, surgery, and radiation. CIO investigators will leverage the interdisciplinary, translational environment at the CC to investigate and optimize how and when to combine drugs, devices, and multimodal imaging navigation. For example, """"""""activatable"""""""" drugs can be injected in a vein or artery, then deployed directly in the tumor with needles or catheters using """"""""medical GPS""""""""a technique that enables the physician to navigate through the body with real-time visualization using the latest advanced imaging technologies, such as magnetic resonance imaging (MRI), positron emission tomography (PET), computed tomography (CT), or ultrasound. Images captured earlier can be reused to guide devices delivering targeted therapy to the location of the disease, making the procedure more cost-effective because it doesn't require the system used to record the first image to be physically present. A prior prostate MRI, for example, can be used to help with guided biopsy or focal ablation by using a """"""""medical GPS""""""""-enabled needle and ultrasound, without requiring, occupying or tying up an MRI system during the procedure. In another example, a thin needle or sound waves can be used to ablate tumors and enhance targeted drug delivery. Energy sources include high-intensity focused ultrasound, freezing, microwaves, laser, and radiofrequency. Researchers also expand investigations into image-guided drug delivery or image-guided """"""""dose painting,"""""""" where the image can be used to prescribe a particular drug dose to a specific region, by combining targeted, activate-able drugs with localized energy or heat to deploy the drug within specially engineered nano-particles. The Center provides a forum to encourage collaborations among researchers and patient-care experts in medical, surgical, urologic, and radiation oncology and interventional radiology. The CC provides an exceptional environment for this type of collaborative translational research and patient care. Other major program components include the development of new image-guided methods for personalized drug investigations (or tracking tissue responses to investigational drugs during drug discovery) and first-in-human investigations involving new drugs, devices, image-guided robotic assistance, molecular probes, and nanoparticles. Many oncologists are not currently familiar with, nor trained in, image based, localized treatment approaches. At the same time, interventional radiologists may lack formal training in oncology. Therefore, education and cross-training is another important part of the program. Significant gaps exist between the various disciplines, between research efforts and patient care, and between diagnosis and treatment. The gaps may be integrated through advanced image methods for localized therapy. Further, cross-disciplinary training programs in interventional oncology suited to these early disease detect &treat paradigms do not yet exist, but would augment existing programs and underline the unique translational atmosphere at the NIH, where bench-to-bedside is the rule. The CIO's collaborative activities are guided by a steering committee with input from multiple ICs with the home-base in the Clinical Centers Radiology and Imaging Sciences Department.
Specific aims i nclude: 1. Develop training and education in Interventional Oncology 2. Develop novel image-guided methods for smart biopsy and biomarker procurement to support targeted therapeutics 3. Support patient care using novel minimally invasive Interventional Oncology techniques 4. Pursue research in novel techniques and technologies in Interventional Oncology This new program is ideally and uniquely positioned to provide an interdisciplinary environment that combines training, patient care, and translational research to accelerate progress in interventional oncology and molecularly targeted interventions. The focus is upon translational models, translational tools, and actual deliverables of translation of multidisciplinary paradigms that meet specific clinical needs.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Clinical Support Services Intramural Research (ZID)
Project #
Application #
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
National Cancer Institute Division of Basic Sciences
Zip Code
Eranki, Avinash; Farr, Navid; Partanen, Ari et al. (2018) Mechanical fractionation of tissues using microsecond-long HIFU pulses on a clinical MR-HIFU system. Int J Hyperthermia 34:1213-1224
An, Julie Y; Sidana, Abhinav; Holzman, Sarah A et al. (2018) Ruling out clinically significant prostate cancer with negative multi-parametric MRI. Int Urol Nephrol 50:7-12
Sidana, Abhinav; Watson, Matthew J; George, Arvin K et al. (2018) Fusion prostate biopsy outperforms 12-core systematic prostate biopsy in patients with prior negative systematic biopsy: A multi-institutional analysis. Urol Oncol 36:341.e1-341.e7
Gold, Samuel A; Hale, Graham R; Bloom, Jonathan B et al. (2018) Follow-up of negative MRI-targeted prostate biopsies: when are we missing cancer? World J Urol :
An, Julie Y; Harmon, Stephanie A; Mehralivand, Sherif et al. (2018) Evaluating the size criterion for PI-RADSv2 category 5 upgrade: is 15 mm the best threshold? Abdom Radiol (NY) :
Thompson, John G; van der Sterren, William; Bakhutashvili, Ivane et al. (2018) Distribution and Detection of Radiopaque Beads after Hepatic Transarterial Embolization in Swine: Cone-Beam CT versus MicroCT. J Vasc Interv Radiol 29:568-574
Bloom, Jonathan B; Gold, Samuel A; Hale, Graham R et al. (2018) ""Super-active surveillance"": MRI ultrasound fusion biopsy and ablation for less invasive management of prostate cancer. Gland Surg 7:166-187
Greer, Matthew D; Lay, Nathan; Shih, Joanna H et al. (2018) Computer-aided diagnosis prior to conventional interpretation of prostate mpMRI: an international multi-reader study. Eur Radiol 28:4407-4417
Mikhail, Andrew S; Pritchard, William F; Negussie, Ayele H et al. (2018) Mapping Drug Dose Distribution on CT Images Following Transarterial Chemoembolization with Radiopaque Drug-Eluting Beads in a Rabbit Tumor Model. Radiology 289:396-404
Calio, Brian P; Sidana, Abhinav; Sugano, Dordaneh et al. (2018) Risk of Upgrading from Prostate Biopsy to Radical Prostatectomy Pathology-Does Saturation Biopsy of Index Lesion during Multiparametric Magnetic Resonance Imaging-Transrectal Ultrasound Fusion Biopsy Help? J Urol 199:976-982

Showing the most recent 10 out of 146 publications